Profilo
Mr. Patrick E.
Dolezal is a Senior Research Analyst at LifeSci Capital LLC.
He focuses on emerging biotechnology and pharmaceutical companies.
His coverage universe includes a diverse range of therapeutic areas, which include gene therapy, gene editing, and hepatology.
He received his undergraduate degree from Indiana University and a graduate degree from New York University.
Posizioni attive di Patrick Dolezal
| Società | Posizione | Inizio |
|---|---|---|
LifeSci Capital LLC
 LifeSci Capital LLC Investment Banks/BrokersFinance LifeSci Capital LLC is a full-service investment bank that offers financial and strategic advisory services, institutional outreach, and research to leading life sciences companies. The private company is based in New York, NY. The company's team of investment bankers has extensive experience at bulge bracket and specialty investment banks. LifeSci Capital's highly regarded team of analysts generates differentiated, proprietary research and covers companies across all major therapeutic areas. The company was founded in 2013 by Andrew Ian McDonald and Michael Yehuda Rice. Andrew Ian McDonald has been the CEO since 2013. | Analyst-Equity | 01/06/2015 |
Formazione di Patrick Dolezal
| New York University | Graduate Degree |
| Indiana University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
LifeSci Capital LLC
LifeSci Capital LLC Investment Banks/BrokersFinance LifeSci Capital LLC is a full-service investment bank that offers financial and strategic advisory services, institutional outreach, and research to leading life sciences companies. The private company is based in New York, NY. The company's team of investment bankers has extensive experience at bulge bracket and specialty investment banks. LifeSci Capital's highly regarded team of analysts generates differentiated, proprietary research and covers companies across all major therapeutic areas. The company was founded in 2013 by Andrew Ian McDonald and Michael Yehuda Rice. Andrew Ian McDonald has been the CEO since 2013. | Finance |
- Borsa valori
- Insiders
- Patrick Dolezal
